Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology

• Sponsor: Zetiq Technologies (Industry)
• Overall Status: Unknown status
• CT.gov ID: NCT01551342
• Collaborator: (none)
• Enrollment: 500
• Locations: 7
• Patients Per Site: 71.4

Study Details

Study Description

Brief Summary

• This study includes two semi-consecutive parts:

• Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.

• Part II Prospective, controlled, blinded part to determine the performance of the CellDetect® device in monitoring bladder cancer recurrence in patients with a history of TCC, using urine cytology samples

• The following subjects will be enrolled:

Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.

Condition or Disease	Intervention/Treatment	Phase
Bladder Cancer Transitional Cell Carcinoma

Detailed Description

Study aim:

1. To calibrate the CellDetect® device for detecting TCC in urine cytology samples.

2. Determine the performance of the CellDetect® device in identifying TCC recurrence in patients with a history of TCC using urine cytology samples.

The study includes two parts:

Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.

Part II Prospective, controlled, blinded part to determine the performance of the CellDetect® device in monitoring bladder cancer recurrence in in patients with a history of TCC, using urine cytology samples

• The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.

Part I - up to 200 urine eligible samples Part II - up to 300 urine eligible samples

Endpoints:

1. To calibrate the CellDetect® device for identifying TCC in urine cytology samples.

2. To determine the performance of the CellDetect® device in identifying recurrence of TCC in urine samples.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 500 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology
• Study Start Date: Jan 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Cystoscopic surveillance, TURT or Cystectomy The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Part A:

*Inclusion Criteria Inclusion criteria will be different for each group subjects.

Group A (Monitoring group):

1. Subjects diagnosed with bladder cancer undergoing routine cystoscopic surveillance, who had normal cystoscopies for at least 12 months..

2. Ability to provide informed consent

3. Age > 18 years

Group B (Positive group):

1. Subject undergoing TURT or cystectomy due to any of the following reasons:

• Subjects with suspected or known TCC (hematuria subjects)

• Subjects with previously diagnosed TCC undergoing routine cystoscopic surveillance.

1. Ability to provide informed consent

2. Age > 18 years

Exclusion Criteria

1. Participation in another clinical trial within last 30 days.

2. Known pregnancy on day of screening.

Part B:

*Inclusion Criteria

Subjects meeting the following criteria (all of them) will be included in the study:

1. Subject with a documented history of TCC and who are undergoing routine cystoscopic surveillance, TURBT or cystectomy

2. At least 4 weeks have passed since any treatment for TCC (including cystoscopy and/or TURBT procedures)

3. Ability to provide informed consent

4. Age ≥ 18 years old

• Exclusion Criteria

Subjects complying with any of the following exclusion criteria will be excluded from the study:

1. Subject with catheters, neobladder or kidney stones.

2. Subject unable to provide a spontaneous urine sample.

3. Subject currently under any cancer drug treatment.

4. No biopsy results available for subjects with positive findings on cystoscopy test, TURBT or cystectomy. [Note: such subjects will be excluded after recruitment and urine collection, as result of the delay in receiving biopsy results].

5. If more than 3 months have passed between urine sample collection and TURBT or cystectomy procedures, and no second sample was taken before undergoing TURBT, subject will be excluded from the study.

6. Subject undergoing TURBT or cystectomy whose biopsy results demonstrated abnormal findings other than TCC.

7. Subject participated in another clinical study within the last 30 days.

8. Known pregnancy on day of screening.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Emek Medical Center	Afula		Israel
2	Urology Department, Bnai Zion Medical Center	Haifa		Israel
3	Urology Department, Hadassah Medical Center Ein Kerem	Jerusalem		Israel
4	Urology Department, Meir Medical Center	Kfar Sava		Israel
5	Urology Department, Rabin Medical Center, Belinson Campus	Petach Tikva		Israel
6	Urology Department, Sourasky Medical Center	Tel Aviv		Israel
7	Urology Department, Sheba Medical Center	Tel Hashomer		Israel

Sponsors and Collaborators

• Zetiq Technologies

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Zetiq Technologies
• ClinicalTrials.gov Identifier: NCT01551342
• Other Study ID Numbers: ZT-CL-04B
• First Posted: Mar 12, 2012
• Last Update Posted: Mar 21, 2014
• Last Verified: Aug 1, 2013

• Keywords provided by Zetiq Technologies: bladder cancer; Transitional cell carcinoma (TCC)
• Additional relevant MeSH terms: Urinary Bladder Neoplasms; Carcinoma, Transitional Cell

Study Results

No Results Posted as of Mar 21, 2014